NL-OMON27803招募中不适用
Phase I interaction study of Docetaxel and Tolbutamide with supplementation of MilkThistle.
The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-AVL)0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients for whom treatment with docetaxel is considered to be
- •of therapeutic benefit, e.g. advanced breast, gastric, esophagus,
- •bladder, ovarian cancer and non-small cell lung cancer, head and neck cancer and prostate cancer;
排除标准
- •1. Any treatment with investigation drugs within 30 days before the start of the study;
- •2. Patients with known alcoholism, drug addiction and/or a psychiatric or physiological condition which in the opinion of the investigator would impair study compliance;
研究者
相似试验
招募中
不适用
Phase I interaction study of Docetaxel and Tolbutamide with supplementation of Milk Thistlemalignant tumors10006291cancerNL-OMON39305Antoni van Leeuwenhoek Ziekenhuis10
已完成
2 期
Phase II Study of Docetaxel and TS-1 Combination Therapy for Outpatients with Relapsed or Refractory Non-small Cell Lung cancerRelapsed or Refractory Non-small Cell Lung CancerJPRN-UMIN000000501Outpatient Oncology Unit Kyoto University Hospital40
终止
3 期
Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based ChemotherapyCarcinoma, Non-Small Cell LungNCT00243204Point Therapeutics400
已完成
2 期
Phase II Study of Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric CancerMetastatic gastric cancer (Advanced or recurrent gastric cancer)JPRN-C000000103Hiroshima Cancer Therapy Development Organization (HiCTDO)50
已完成
不适用
Phase I/II study of the combination of docetaxel, CDDP and S-1 in patients with unresectable advanced gastric cancerunresectable advanced gastric cancerJPRN-C000000080Fourth Department of Internal Medicine, Sapporo Medical University40